Canakinumab
Mechanism :
Canakinumab reduces inflammation by binding to interleukin-1 beta (IL-1beta) and preventing interaction with cell surface receptors.
Indication :
- Cryopyrin-associated periodic syndromes
- Familial Mediterranean fever
- Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
- Tumor necrosis factor (TNF) receptor associated periodic syndrome (TRAPS)
- Systemic juvenile idiopathic arthritis: Treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years and older.
Contraindications :
Hypersensitivity to canakinumab or any component of the formulation.
Dosing :
Subcutaneous
Cryopyrin-associated periodic syndromes (CAPS):
Children ≥4 years and Adolescents:
15 to 40 kg: 2 mg/kg every 8 weeks; may increase to 3 mg/kg if response inadequate.
Familial Mediterranean Fever (FMF), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS):
150 mg (>40 kg) or 2 mg/kg (≤40 kg) every 4 weeks; may increase to 300 mg (>40 kg) or 4 mg/kg (≤40 kg) every 4 weeks if response is not adequate.
Systemic juvenile idiopathic arthritis (SJIA):
Children ≥2 years and ≥7.5 kg and Adolescents:
4 mg/kg every 4 weeks. Maximum: 300 mg per dose
Adverse Effect :
Headache, vertigo, weight gain, diarrhea, upper abdominal pain, nausea, infection, influenza, injection site reaction, musculoskeletal pain, nasopharyngitis, rhinitis, hypocalcemia, proteinuria, neutropenia, eosinophilia, thrombocytopenia, hyperbilirubinemia, antibody development.
Interaction :
Anti-TNF Agents: May enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.
Interleukin-1 Inhibitors: May enhance the adverse/toxic effect of Canakinumab.
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines.
Hepatic Dose :
No dosage adjustments are recommended.